Gastrointestinal and Hepatobiliary Oncology
Gastroesophageal adenocarcinoma, gastric cancer, and colorectal cancer are central areas of interest, alongside multiple biliary tract cancers and cholangiocarcinoma subtypes. The portfolio also includes hepatocellular carcinoma across intermediate, advanced, and unresectable disease settings.
- Intrahepatic cholangiocarcinoma
- Extrahepatic cholangiocarcinoma
- Metastatic colorectal cancer
- Advanced hepatocellular carcinoma
- Esophagogastric adenocarcinoma
Research activity also covers biomarker-defined disease groups, including FGFR2-altered and HER2-positive tumors in the upper gastrointestinal tract.
Thoracic and Lung Cancer
The sponsor funds studies in non-small cell lung cancer, with attention to locally advanced, metastatic, and unresectable disease. Its research extends to molecularly defined subgroups such as ALK-positive NSCLC and adenocarcinoma-specific populations.
- ALK-positive NSCLC
- Unresectable stage III NSCLC
- Locally advanced metastatic NSCLC
- Thoracic radiotherapy
Clinical work in this area includes treatment strategies for patients who are not suitable for standard systemic approaches, as well as perioperative and organ-preserving settings.
Skin, Urothelial, and Rare Solid Tumors
Trial activity includes basal cell carcinoma, Merkel cell carcinoma, and penile squamous cell carcinoma, reflecting interest in uncommon malignancies with limited treatment options. The sponsor also supports research in urothelial carcinoma and other advanced solid tumors.
- Basal cell carcinoma
- Merkel cell carcinoma
- Penile squamous cell carcinoma
- Urothelial carcinoma
- Advanced solid tumors
These studies span locally advanced, metastatic, and refractory disease contexts, with emphasis on difficult-to-treat tumor types.
Hematologic Malignancies
The research portfolio includes aggressive B-cell lymphoma, large B-cell lymphoma, and myelofibrosis. These programs address both newly diagnosed and relapsed or refractory disease, as well as patients with limited tolerance for intensive treatment.
- Large B-cell lymphoma
- Aggressive B-cell lymphoma
- Myelofibrosis
- Relapsed/refractory lymphoma
Additional interest is shown in combinations involving CAR-T cell therapy and other immunotherapy-based approaches in hematologic disease.
Targeted and Immuno-Oncology in Biomarker-Defined Disease
Many trials focus on immuno-oncology and targeted therapy across biomarker-selected cancers, including HER2-positive, PD-L1-positive, FGFR2-fusion, and IDH1-mutant disease. This includes interest in breast cancer and selected gastrointestinal tumors with actionable molecular features.
- HER2-positive breast cancer
- PD-L1-positive disease
- FGFR2-fusion tumors
- IDH1-mutant cholangiocarcinoma
- Combination immunotherapy
Research in this domain also includes endocrine-sensitive breast cancer and multiple solid tumors treated through biomarker-guided strategies.
